['Long-term opioid therapy has been found to have a strong impact on the hypothalamic-pituitary-gonadal axis that can be manifested clinically by sexual dysfunction (SD). This event is rarely reported and thus unnoticed and undertreated.', 'To analyze the presence of SD in a large group of patients receiving long-term opioids.', 'A descriptive, cross-sectional pilot study of sexual health was conducted for 2 years in 750 consecutive ambulatory patients with chronic non-cancer pain (CNP) receiving opioids for at least 12 months. Cases that reported SD and matched controls were included. Standardized questionnaires and medical record reviews were used to assess rates of pain at diagnosis, daily morphine equivalent doses, and opioid adverse effects.', 'Sexual function was determined by the Female Sexual Function Index (FSFI; scores\xa0= 2-36) and the International Index of Erectile Function erectile function domain (IIEF-EF; scores\xa0= 1-30).', 'Thirty-three percent of 33% of 750 patients with CNP recorded SD based on their spontaneous notification at the pain unit. Men reported SD significantly more frequently than women (33% vs 25%, respectively, P < .05), although they reported having a regular partner (84% vs 70%, P\xa0= .03) and a sexually active life (69% vs 34%, respectively, P\xa0= .00) significantly more often. FSFI scores were significantly influenced by sexual activity in lubrication and arousal. IIEF scores were significantly determined by age in satisfaction with sexual intercourse and overall satisfaction. The morphine equivalent dose was significant higher in men than in women (38%; median\xa0= 70 mg/d, interquartile range\xa0= 43.1-170, 115.5 ± 110.3 mg/d vs median\xa0= 60 mg/d, interquartile range\xa0= 30-100.6, 76.67 ± 63.79 mg/d, P\xa0= .016) at the same mean intensity of pain (P\xa0= .54), which correlated to FSFI scores (r\xa0=\xa0-0.313, P\xa0= .01).'] Do opioids Increase Sexual Dysfunction in Patients With Non-Cancer Pain?